Innovative Therapeutics in Oncology and Neuroscience
32
TIVDAK
First and Only U.S. Approved ADC for Recurrent or Metastatic Cervical Cancer with
Disease Progression on or After Chemotherapy
innova TV 205 Combination Data in 1L Cervical Cancer
Presented at ASCO 20221
1L TV + KEYTRUDA
(N=32)²
1L TV + carbo
(N=33)³
Confirmed ORR
40.6%
(23.7, 59.4)
54.5%
(36.4, 71.9)
•
Complete response rate
15.6%
12.1%
Partial response rate
25.0%
42.4%
Median DOR
Not Reached
8.6
Approved
Current Status & Next Step
FDA approval in 2L+ CC in September
2021
Broad development program in cervical
cancer and other solid tumor indications
ongoing
Potential China NDA submission in 2L+
CC in 2024
(U.S.)
Dose expansion cohorts of TV in combination with KEYTRUDA or
carboplatin in R/M CC demonstrated encouraging anti-tumor activity
The safety profiles in combination were manageable and tolerable and in
line with the safety profiles seen with the individual agents
⚫ innovaTV 205 trial is ongoing, and a new cohort will be added to
investigate the combination of TV + carboplatin and pembrolizumab +
bevacizumab as 1L treatment for R/M CC
Core Opportunity
~110K annual incidence of cervical cancer
in China 4, with limited treatment options
for patients who progress on or after
chemotherapy
Abbreviations: Tivdak (TV), recurrent or metastatic cervical cancer (R/M CC), carboplatin (carbo), first-line (1L).
Notes: (1) Lorusso et al., ASCO 2022; (2) median follow-up of 18.8 months; (3) median follow-up of 14.6 months; (4) Globocan 2020.
Clinical Data -
OncologyView entire presentation